Viewing offline content

Limited functionality available

Dismiss
Deloitte UK
  • Services

    Highlights

    • CFO Advisory

      Bringing together the best of Deloitte to support CFOs. Whether developing skills or navigating business challenges, CFO Advisory can support.

    • Deloitte Ventures

      Connecting our clients to emerging start-ups, leading technology players and a whole raft of new Deloitte talent.

    • Towards net zero together

      Discover the people leading the change and what could be possible for your business.

    • Audit & Assurance

      • Audit
      • Audit - IASPlus
      • Assurance
    • Consulting

      • Core Business Operations
      • Customer and Marketing
      • Enterprise Technology & Performance
      • Human Capital
      • Strategy, Analytics and M&A
    • Financial Advisory

      • Mergers & Acquisitions
      • Performance Improvement
    • Legal

      • Legal Advisory
      • Legal Managed Services
      • Legal Management Consulting
    • Deloitte Private

      • Family Enterprises
      • Private Equity
      • Emerging Growth
    • Risk Advisory

      • Accounting and Internal Controls
      • Cyber and Strategic Risk
      • Regulatory and Legal
    • Tax

      • Global Business Tax Services
      • Indirect Tax
      • Global Employer Services
  • Industries

    Highlights

    • Ecosystems & Alliances

      An engine to embrace and harness disruptive change

    • Resilience Reimagined

      Resilient organisations thrive before, during and after adversity. How will you become more resilient?

    • Consumer

      • Automotive
      • Consumer Products
      • Retail, Wholesale & Distribution
      • Transportation, Hospitality & Services
    • Energy, Resources & Industrials

      • Industrial Products & Construction
      • Mining & Metals
      • Energy & Chemicals
      • Power, Utilities & Renewables
      • Future of Energy
    • Financial Services

      • Banking
      • Capital Markets
      • Insurance
      • Investment Management
      • Real Estate
      • FinTech & Alternative Finance
    • Government & Public Services

      • Health & Human Services
      • Defence, Security & Justice
      • Central Government
      • Infrastructure, Transport and Regional Government
    • Life Sciences & Health Care

      • Health Care
      • Life Sciences
    • Technology, Media & Telecommunications

      • Telecommunications, Media & Entertainment
      • Technology
  • Insights

    Deloitte Insights

    Highlights

    • Deloitte Insights Magazine

      Explore the latest issue now

    • Deloitte Insights app

      Go straight to smart with daily updates on your mobile device

    • Weekly economic update

      See what's happening this week and the impact on your business

    • Strategy

      • Business Strategy & Growth
      • Digital Transformation
      • Governance & Board
      • Innovation
      • Marketing & Sales
      • Private Enterprise
    • Economy & Society

      • Economy
      • Environmental, Social, & Governance
      • Health Equity
      • Trust
      • Mobility
    • Organization

      • Operations
      • Finance & Tax
      • Risk & Regulation
      • Supply Chain
      • Smart Manufacturing
    • People

      • Leadership
      • Talent & Work
      • Diversity, Equity, & Inclusion
    • Technology

      • Data & Analytics
      • Emerging Technologies
      • Technology Management
    • Industries

      • Consumer
      • Energy, Resources, & Industrials
      • Financial Services
      • Government & Public Services
      • Life Sciences & Health Care
      • Technology, Media, & Telecommunications
    • Spotlight

      • Deloitte Insights Magazine
      • Press Room Podcasts
      • Weekly Economic Update
      • COVID-19
      • Resilience
      • Top 10 reading guide
  • Careers

    Highlights

    • Hear from our people

      At Deloitte, our people are at the heart of what we do. Discover their stories to find out more about Life at Deloitte.

    • Careers Home

  • UK-EN Location: United Kingdom-English  
  • UK-EN Location: United Kingdom-English  
    • Dashboard
    • Saved Items
    • Content feed
    • Profile/Interests
    • Account settings

Welcome back

Still not a member? Join My Deloitte

2020 global life sciences outlook

by Greg Reh
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
Deloitte Insights
  • Strategy
    Strategy
    Strategy
    • Business Strategy & Growth
    • Digital Transformation
    • Governance & Board
    • Innovation
    • Marketing & Sales
    • Private Enterprise
  • Economy & Society
    Economy & Society
    Economy & Society
    • Economy
    • Environmental, Social, & Governance
    • Health Equity
    • Trust
    • Mobility
  • Organization
    Organization
    Organization
    • Operations
    • Finance & Tax
    • Risk & Regulation
    • Supply Chain
    • Smart Manufacturing
  • People
    People
    People
    • Leadership
    • Talent & Work
    • Diversity, Equity, & Inclusion
  • Technology
    Technology
    Technology
    • Data & Analytics
    • Emerging Technologies
    • Technology Management
  • Industries
    Industries
    Industries
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Tech, Media, & Telecom
  • Spotlight
    Spotlight
    Spotlight
    • Deloitte Insights Magazine
    • Press Room Podcasts
    • Weekly Economic Update
    • COVID-19
    • Resilience
    • Top 10 reading guide
    • UK-EN Location: United Kingdom-English  
      • Dashboard
      • Saved Items
      • Content feed
      • Profile/Interests
      • Account settings
    6 minute read 10 January 2020

    2020 global life sciences outlook Creating new value, building blocks for the future

    6 minute read 10 January 2020
    • Greg Reh United States
    • Save for later
    • Download
    • Share
      • Share on Facebook
      • Share on Twitter
      • Share on Linkedin
      • Share by email
    • Creating new value, building blocks for the future
    • Creating new value
    • Leveraging opportunities and increasing efficiencies
    • Building blocks for the future
    • Looking ahead: Sales trajectories

    As the sector moves toward a future of data-driven technologies, this year’s global life sciences sector outlook tries to answer questions around creating new value, leveraging opportunities, and investing in the future.

    Creating new value, building blocks for the future

    Biopharma and medtech organizations are in the fast lane, headed toward a future driven by evolving, data-driven technologies. As organizations strive to make sense of all the data signals, is it time to take a break to refuel and rethink what is being measured? In a rapidly changing world, what metrics really matter?

    Learn more

    Learn more about the 2020 global life sciences outlook

    Download the summary or full report

    View the infographic

    Subscribe to receive related content from Deloitte Insights

    Download the Deloitte Insights and Dow Jones app

    To find the next generation of key performance indicators, there are several questions organizations could be asking: What can be done to reduce complexity in the patient experience? What is the next level of performance, and how to get there in the next year? Is there adequate visibility of products, costs, and operations to help make timely, informed decisions? Is there a need to acquire, build, or partner for additional capabilities?

    The 2020 global life sciences outlook helps answer these questions and more. As leaders set their sights on the road to 2020 and look to shift their strategic gears, here’s what they can consider:

     

    Creating new value

    Leaders should more deeply consider ways to increase value and meaning for all stakeholders. The experiences of workers, customers (patients), and ecosystem partners (vendors, alliances, advocacy groups) are interrelated.

    Creating value for patients, care teams, and partners. To create value for patients, organizations can focus on providing a holistic patient experience—mapping all the touchpoints that patients may experience throughout their journey and with their care teams. Building an empathetic solution—such as a “patient hub”—could help patients and caregivers connect digitally and address needs ranging from diagnosis to maintenance. Similarly, medtech companies can work to gain a deeper understanding of the end user, develop more user-friendly devices, and look at ways to offer patient-centered services in nonclinical settings.1

    In an era of precision medicine, clinical trials should be representative of the patients who will eventually use a drug or therapy. Efforts are underway to make trials more inclusive and increase participation from minorities and the elderly.2 Stakeholders can look at options such as telemedicine to reduce complexity and provide people with virtual access to clinical trials.

    Creating value for the workforce. In the workplace, when conditions, tools, and requirements change rapidly, organizations, systems, and practices should assimilate these changes. To create value for the workforce, life sciences and medtech organizations can look at emerging technologies, meaningful work, and flexible work models. Heading into 2020, leaders will likely look at how jobs can be redesigned and work reimagined around human-machine collaboration, working with machines to think exponentially.

    Creating value in the market, tracking discernible change. With a rocky market and talks of recession in many parts of the world, biopharma companies appear to be biding their time to ink merger and acquisition deals. In biotech, ballooning valuations may be getting a reality check,3 but health-related technology companies are now being valued at over a billion dollars, with many reaching unicorn4 status in the last year.5 Medtech has also entered a billion-dollar era, having seen its largest year for multiple billion-dollar deals.6

    In 2020, the shift is expected to continue toward rare diseases and treatments for unmet needs. Biopharma is making the move to invest in or acquire companies specializing in gene therapies. Manufacturing is expected to be a key differentiator for gene therapies. Large pharmaceutical companies, contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs) are adding capacity,7 either from new facilities, expansions, or acquisitions.8 The demand for additional manufacturing capacity will likely be exacerbated by accelerated regulatory approvals.

    Technology investments, either through acquisition or software licensing, will likely continue to play a dominant role in life sciences.9 In addition to compliance, risk management, and product lifecycle management (PLM) software, organizations should look to continue investing in applications to enhance real-world evidence and drug discovery.

    The growing demand for personalized medicine and orphan drugs is driving R&D investments in large-molecule products.10 R&D was found to be a source of diminishing return on capital (ROC), especially having fewer assets in the late-stage pipeline and lower potential sales per asset.11 Return on capital could be one of the key metrics that matter for 2020—providing insights for organizations that are considering potential partners and a new understanding of the efficiency of allocating capital under control to drive profitability.12

    In the future, smaller companies may ultimately take an increasing share of the market from Big Pharma by developing and commercializing products independently.13

    Leveraging opportunities and increasing efficiencies

    Accelerating R&D using technology. Artificial intelligence (AI) is ushering in a new era of intelligent drug discovery, and the trend is likely to continue in 2020. There has been an explosion of AI startups, and tech giants such as Google have also made advances in AI-driven biochemistry that are expected to lead to new developments.14 Pharmaceutical companies are expected to continue to leverage partnerships.

    Drug approval rates have also witnessed a spike. Fast-tracking new drugs is becoming “a new normal,” but there are also concerns over quality, safety, and costs.15

    Increasing operational efficiency. The demand for small-volume, personalized medicines is driving operations away from large-scale bulk production to multiproduct facilities. The lens is gradually zooming in on smart factories of the future that may offer digital automation solutions, industrial IoT connectivity, and flexible manufacturing processes.16 With a digitized core, the number of days it takes to release a drug product could potentially be reduced from 100 days to seven.

    Data-driven manufacturing is generating more excitement heading into 2020, providing a renewed focus on quality. Companies are being nudged to revisit their approach toward managing the cost of quality and compliance, and businesses are expected to be more agile. With new technologies such as AI and augmented reality (AR), organizations could track productivity in real time, as well as reduce the risk of human error.

    Partnering with other players and leveraging outsourcing opportunities are likely to be a huge success factor. Partner expertise could help address manufacturing, supply chain, and distribution challenges. Key outsourcing areas could be cell therapy manufacturing and big data capabilities.17

    Building blocks for the future

    Innovative financing for innovative therapies. Innovative therapies address unmet needs but typically carry high costs. Gene therapies, for example, are not just being touted as treatments but as cures. However, public and private systems will not likely be able to absorb the prices of these drugs. In 2020, companies are likely to move beyond just selling therapies and enter the business of health care financing—innovating drug pricing and reimbursement.

    The commercialization of gene and cell therapies comes at a time of wider drug price scrutiny from policymakers and the public. In 2020, drug pricing, health care expenditures, and market accessibility will likely continue to be the main concerns.18

    Digital transformation in biopharma and medtech. Devices and the data they generate are likely to inspire the development of new analytics tools, generating insights that drive personalized, real-time decision-making and improve patient outcomes.19 While medtech companies may consider technology companies as competitors, collaborations may help develop more consumer-friendly devices.20

    Both medtech and technology companies will continue to come under consumers’ scrutiny around data, privacy, and security. In 2020, expect the debate on data ownership and ethics to continue.

    Marrying innovation with social good. Research shows that corporate social responsibility (CSR) adds value to pharma companies’ corporate financial performance.21 Increasingly, stakeholders, including investors, appear to be scrutinizing pharmaceutical firms’ environmental and social performance. In addition to companies voluntarily taking up initiatives that are beneficial for society at large, some governments are also making CSR spending mandatory. Companies are likely to look at ways, including public-private partnerships, to more closely align CSR with innovation and patient programs, as it will not just benefit them but society as well.

    Looking ahead: Sales trajectories

    What’ll sell? Worldwide prescription drug sales are projected to have a positive compound annual growth rate (CAGR) of 6.9 percent from 2019 to 2024. Oncology is expected to have almost a 20 percent share of the worldwide market and a CAGR of 11.4 percent by 2024. Over the same period, worldwide orphan drug sales are expected to have double the CAGR of nonorphan drugs, at 12.3 percent. The in vitro diagnosis (IVD) segment is the largest medtech segment globally, accounting for a market share of 12.9 percent in 2018,22 and is expected to remain the number one device area in the foreseeable future.23

    What will not sell? In 2020, clouds of uncertainty will loom large over drug pricing, and challenges may come from lower investments in R&D as a proportion of sales (which is expected to drop from 21.6 percent in 2018 to 18 percent in 2024). By 2024, sales worth US$198 billion are at risk due to patent expiries, and a decline is projected for anti-rheumatics (-1.0 percent CAGR).24

    As for medtech companies, downstream pricing pressures, nontraditional challengers, stringent regulations, and operational inefficiencies due to industry consolidation are forcing them to implement effective cost-reduction strategies to remain competitive. Future success can depend on being proactive and leveraging recent advances in digital technologies.

    To learn more, read the full report: 2020 global life sciences outlook: Creating new value, building blocks for the future.

    Acknowledgments

    The author would like to thank Terry Koch of Deloitte Touche Tohmatsu Limited, Sarah Thomas of Deloitte Services LP, Karen Thomas of Deloitte LLP, and Angela Dunn for their contributions to this report.

    Cover image by: Edu Fuentes

    Endnotes
      1. Pedro Arboleda et al., Winning in the future of medtech: Novel partnerships with consumer tech to transform care delivery, Deloitte Insights, September 19, 2019. View in article

      2. National Institute on Aging, “Recruiting Older Adults into Research (ROAR) presentation toolkit,” January 14, 2019. View in article

      3. Amy Brown, “Bloated on arrival? Biotech's weightiest new issues,” Evaluate Vantage, October 23, 2019. View in article

      4. Investopedia, “Unicorn,” October 15, 2019. View in article

      5. Andy White and Priyamvada Mathur, “Meet the unicorn class of 2019,” PitchBook, December 12, 2019. View in article

      6. Evaluate Vantage, Pharma, biotech & medtech half-year review 2019, July 31, 2019. View in article

      7. Patricia Van Arnum, “Cell and gene therapies: A manufacturing view,” DCAT Value Chain INSIGHTS, April 24, 2019. View in article

      8. Pharmaceutical Technology, “Future of gene therapy manufacturing is a concern for investors and industry alike,” May 30, 2019. View in article

      9. Misho Markovski and Andrej Micik, “Top 10 life sciences software vendors, market size and market forecast 2018-2023,” Apps Run the World, December 9, 2019. View in article

      10. Ian Lloyd, Pharma R&D annual review 2019, Pharma Intelligence, 2019. View in article

      11. Teresa Leste, Yakir Siegal, and Maulesh Shukla, Return on capital performance in life sciences and health care: How have organizations performed and where are best bets going forward?, Deloitte Insights, April 30, 2019. View in article

      12. Ibid. View in article

      13. The Deloitte Centre for Health Solutions, Ten years on: Measuring the return from pharmaceutical innovation 2019, 2019.. View in article

      14. Mohammed AlQuraishi, “AlphaFold @ CASP13: ‘What just happened?',” blog, Some Thoughts on a Mysterious Universe, December 9, 2018. View in article

      15. Advisory Board, “'A new normal': FDA is fast-tracking more drugs than ever, but is that safe?,” July 10, 2019. View in article

      16. Rockwell Automation, The facility of the future, January 2019. View in article

      17. Joseph Constance, “Pharma exec’s 2020 pipeline report,” Pharmaceutical Executive 39, no. 11 (2019). View in article

      18. EvaluatePharma, World preview 2019, outlook to 2024, June 4, 2019. View in article

      19. Arboleda et al., Winning in the future of medtech. View in article

      20. Ibid. View in article

      21. Maung Min, Mark Esposito, and Francois Desmoulins-Lebeault, “Should pharmaceutical companies engage in corporate social responsibility?,” Journal of Management Development 36, no. 1 (2017): 58–70. View in article

      22. Fortune Business Insights, Medical devices market size, share and industry analysis by type, end user, and regional forecast, 2019 – 2025, November 2019. View in article

      23. EvaluateMedTech, World preview 2018, outlook to 2024, September 2018. View in article

      24. EvaluatePharma, World preview 2019, outlook to 2024. View in article

    Show moreShow less

    Topics in this article

    Pharmaceutical , Life Sciences

    Life Sciences & Health Care

    The Deloitte Touche Tohmatsu Limited's life sciences & health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of today's life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today's environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

    Learn more
    Get in touch
    Contact
    • Greg Reh
    • Global Life Sciences Sector leader
    • Deloitte Touche Tohmatsu Limited
    • grreh@deloitte.com
    • +1 215 977 7559

    Download Subscribe

    Related content

    img Trending

    Interactive 3 days ago

    Learn more about the future of biopharma

    • Life Sciences Collection
    • Intelligent drug discovery Article3 years ago
    • Intelligent biopharma Article3 years ago
    • Maintaining value in pharmaceutical compliance Article3 years ago
    • Tackling digital transformation in life sciences Article3 years ago
    • Optimizing biopharma market access Article3 years ago
    Greg Reh

    Greg Reh

    Deloitte Global Life Sciences & Health Care Leader

    Greg serves as the Deloitte Global Life Sciences & Health Care Industry Leader. In this role, he advises life sciences and health care clients and practice leaders within Deloitte’s global network; and is responsible for the overall industry group that conducts research and provides consulting, advisory, tax and audit services to clients in the industry. The global life sciences and health care industry group is comprised of over 20,000 colleagues in more than 90 countries that work with pharmaceutical, biotech, medtech, payer, provider and government clients. Greg also leads Deloitte’s relationship with one the world’s largest healthcare companies, which entails enabling and coordinating client teams around the world. Prior to his current roles, he served as the US life sciences leader; and as the global life sciences leader. Greg has more than 25 years of experience which includes working with multinational pharmaceutical, biotechnology, and chemical manufacturing organizations where he led consulting engagements in support of regulatory, clinical, commercial and manufacturing operations. His engagements focused on technology strategy and solution development; business-technology enabled transformation and the management of change. Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania. Greg holds an MS from the University of Pennsylvania, and a BSME from Drexel University.

    • grreh@deloitte.com
    • +1 215 977 7559

    Share article highlights

    See something interesting? Simply select text and choose how to share it:

    Email a customized link that shows your highlighted text.
    Copy a customized link that shows your highlighted text.
    Copy your highlighted text.

    2020 global life sciences outlook has been saved

    2020 global life sciences outlook has been removed

    An Article Titled 2020 global life sciences outlook already exists in Saved items

    Invalid special characters found 
    Forgot password

    To stay logged in, change your functional cookie settings.

    OR

    Social login not available on Microsoft Edge browser at this time.

    Connect Accounts

    Connect your social accounts

    This is the first time you have logged in with a social network.

    You have previously logged in with a different account. To link your accounts, please re-authenticate.

    Log in with an existing social network:

    To connect with your existing account, please enter your password:

    OR

    Log in with an existing site account:

    To connect with your existing account, please enter your password:

    Forgot password

    Subscribe

    to receive more business insights, analysis, and perspectives from Deloitte Insights
    ✓ Link copied to clipboard
    • Contact us
    • Careers at Deloitte
    • Submit RFP
    Follow Deloitte Insights:
    Global office directory Office locations
    UK-EN Location: United Kingdom-English  
    About Deloitte
    • Home
    • Press releases
    • Newsroom
    • Deloitte Insights
    • Global Office Directory
    • Office locator
    • Contact us
    • Submit RFP
    Services
    • Audit & Assurance
    • Consulting
    • Financial Advisory
    • Legal
    • Deloitte Private
    • Risk Advisory
    • Tax
    Industries
    • Consumer
    • Energy, Resources & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media & Telecommunications
    Careers
    • Careers Home
    • About Deloitte
    • About Deloitte UK
    • Accessibility statement
    • Cookies
    • Health and Safety
    • Modern Slavery Act Statement
    • Privacy statement
    • Regulators & Provision of Services Regulations
    • Deloitte LLP Subprocessors
    • Supplier Standard Terms & Conditions
    • Terms of Use

    © 2023. See Terms of Use for more information.

     

    Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see About Deloitte to learn more about our global network of member firms.

     

    Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HQ, United Kingdom. A list of members of Deloitte LLP is available at Companies House.